Blog

Teva Launches AirDuo™ RespiClick® and its Authorized Generic

[Press Release] Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol First and Only Generic Fluticasone Propionate and Salmeterol (ICS/LABA) Inhaler Available in the U.S. JERUSALEM, April 20, 2017 – Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the simultaneous launch of AirDuo™ RespiClick® (fluticasone propionate and salmeterol) inhalation powder and its authorized generic for the treatment...

Asthma and Allergy Research Review January-March 2017

The Asthma and Allergy Foundation of America will recap some of the top research about allergies and asthma every three months. Here is a look at studies reported between January and March. Read about how treating homes for cockroaches can improve children's asthma, a possible link between insomnia and developing asthma, the safety of allergy immunotherapy and more.

World Allergy Week Highlights the Agony of Chronic Hives

Do you suffer from hives? This week marks World Allergy Week, and the theme for this year’s event is The Agony of Hives - What to do when welts and swelling do not go away. The medical name for hives is urticaria. Hives are a common sign of an allergic reaction. Hives can also occur due to other causes, including a viral infection. Learn more by visiting Hives (Urticaria) . Find out when to call your health care provider, and when to go to the emergency room or call 911. Hives can occur due...

GlaxoSmithKline Recalling Ventolin Inhalers for Possible Package Leakage

The Asthma and Allergy Foundation of America is a non-profit organization and we are reporting this recall to inform people with asthma who rely on this medication. If you have questions, call the GlaxoSmithKline response center, the manufacturer of Ventolin: 1-888-825-5249. GlaxoSmithKline (GSK) issued a voluntary Class II recall on April 4, 2017 for three lots of Ventolin® HFA 200D Inhalers from U.S. hospitals, pharmacies, retailers and wholesalers as a precautionary measure. It is not a...

AAFA Announces Departure of CEO Dr. Cary Sennett

April 3, 2017, Landover, MD – Today, the Board of Directors of the Asthma and Allergy Foundation of America (AAFA) announces the departure of Dr. Cary Sennett, MD, PhD, FACP. “It is with extreme gratitude that I thank Dr. Sennett for his service to the asthma and allergy community,” said Board Chair, Heidi Bayer. “Dr. Sennett helped us create a vision for the future of AAFA which puts our constituents in the forefront of every program and policy decision with a goal of helping them to live a lif

Health Insurance 101 for People With Asthma and Allergies (Video and Resources)

The Asthma and Allergy Foundation of America (AAFA) hosted a webinar on Thursday, March 30, 2017, about Health Insurance 101 for People with Asthma and Allergies. Watch video on YouTube Our guest speaker was Prue Fitzpatrick, MPH, a member of the Board of Directors for AAFA. She has a background in health care policy, having been involved with recent health reform policy development and implementation, as well as experience working within the insurance industry. Ms. Fitzpatrick discussed:...

New Eczema Drug Dupixent Approved by FDA

The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable. Dupixent can be used with or without topical corticosteroids.

×
×
×
×